{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events to calculate via KM methodology","groupId":"OG000","lowerLimit":"2.2","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events to calculate via KM methodology","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Time to event will be estimated using the product-limit method of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nDexamethasone: Given PO","id":"OG000","title":"Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)"},{"description":"Patients receive lenalidomide PO as in Arm I.\n\nLenalidomide: Given PO","id":"OG001","title":"Arm II (Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"One patient in Arm1 and two patients in Arm 2 were not analyzed because their data were not collected.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"years"}